EviCore
By EVERNORTH

Radiation Oncology Guidelines
Executive Summary
Effective Date: December 01, 2026

Section Name	Version/ Release Number	CPT Code(s)	Section Number/Policy Number	Summary of change	Will this change impact the current clinical decision-making?	If yes, both or unsure to prior Column, will it impact more than 1 case per week?	Provide citable, peer-reviewed/society references for all changes, except for editorial changes (i.e. formatting, wordsmithing, restructuring changes that don't impact clinical content)
Radiation Oncology Guidelines	4.0.2026	N/A	Throughout	All sections upversioned to v4.0.2026.	No	N/A	N/A
Pluvicto® (lutetium Lu 177 vipivotide tetraxetan)	4.0.2026	79101 A9607	RO.RX.144.A	Changed from no PSMA-negative lesions to no dominant PSMA-negative lesions.	Yes, More Approvals	No	National Comprehensive Cancer Network. (2026). Prostate Cancer (Version 7.2026).
Pluvicto® (lutetium Lu 177 vipivotide tetraxetan)	4.0.2026	79101 A9607	RO.RX.144.A	Added an indication for Pluvicto in individuals with metastatic castration-sensitive prostate cancer with no prior treatment or minimal prior treatment.	Yes, More Approvals	More than 1 case per week	1. National Comprehensive Cancer Network. (2026). Prostate Cancer (Version 7.2026). 2. Tagawa, S. T., Sartor, O., Piulats, J. M., Saad, F., Fizazi, K., Reid, A., Beltran, H., Kramer, G., Mahammedi, H., Eiber, M., Gupta, S., Castellano, D., Hauke, R., Kim, H., Kwak, C., Pang, S. T., Barthélémy, P., Dai, D., Lee, J. L., ... Morris, M. J. (2026). [^{177}Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): A phase 3 randomised, controlled trial. The Lancet, 408, 793–807. https://doi.org/10.1016/S0140-6736(26)01092-5
Pluvicto® (lutetium Lu 177 vipivotide tetraxetan)	4.0.2026	79101 A9607	RO.RX.144.A	Editorial and grammatical updates as needed.	No	N/A	N/A
Pluvicto® (lutetium Lu 177 vipivotide tetraxetan)	4.0.2026	N/A	RO.RX.144.A	Discussion section updated.	No	N/A	N/A
Pluvicto® (lutetium Lu 177 vipivotide tetraxetan)	4.0.2026	N/A	RO.RX.144.A	References section upated.	No	N/A	N/A